RA
TNXP icon

Rosalind Advisors’s Tonix Pharmaceuticals TNXP Stock Holding History

Rosalind Advisors’s Portfolio TNXP Stock Details TNXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-282
Closed -$19.6K – 39
2024
Q2 		$19.6K Hold
282
– – 0.02% 39
2024
Q1 		$168K Hold
282
– – 0.16% 31
2023
Q4 		$363K Buy
+282
New +$454K 0.3% 30

Other funds holding TNXP

Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return
MG
Marex Group London $23.6B AUM 57.16% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Vanguard Personalized Indexing Management
Vanguard Personalized Indexing Management Oakland, California $12.2B AUM 47.93% 1-Year Est. Return

Rosalind Advisors's TNXP Position: Q3 2024 in Review

Rosalind Advisors sold out of Tonix Pharmaceuticals (TNXP) in Q3 2024, closing a stake of 282 shares — an estimated $19.6K sold.

Rosalind Advisors first reported a position in TNXP in Q4 2023 and held it in 3 quarters. The position peaked at $363K in Q4 2023. 16 funds tracked by Wall St. Rank hold TNXP as of Q3 2024.

  • Rosalind Advisors reported no remaining Tonix Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Rosalind Advisors sold 282 Tonix Pharmaceuticals shares in Q3 2024, an estimated $19.6K.
  • Rosalind Advisors first reported a position in Tonix Pharmaceuticals in Q4 2023 and held it in 3 quarters.
  • Rosalind Advisors's Tonix Pharmaceuticals position peaked at $363K in Q4 2023.
  • 16 funds tracked by Wall St. Rank held Tonix Pharmaceuticals as of Q3 2024.

Based on Rosalind Advisors's 13F filing for Q3 2024, filed 30 Oct 2024.